New pill aims to ease schizophrenia episodes
NCT ID NCT07467993
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental oral drug called GXV813 in 142 hospitalized adults with schizophrenia. The goal is to see if it safely reduces symptoms like hallucinations and withdrawal during an acute episode. Participants are randomly assigned to receive GXV813 or a placebo, and neither they nor their doctors know which they get.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GXV813 (an oral drug)
What this could lead to
If it works, this could point toward a new treatment option for acute schizophrenia episodes, helping reduce severe symptoms.
What could go wrong
This is an early Phase 2a trial with only 142 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Arch Clinical Trials LLC
RECRUITINGSt Louis, Missouri, 63141, United States
Contact
-
CNRI Los Angeles LLC
RECRUITINGPico Rivera, California, 90660, United States
Contact
-
CenExel iResearch
RECRUITINGDecatur, Georgia, 30030, United States
Contact
-
Novartis Investigative Site
RECRUITINGKazanlak, Bulgaria, 6100, Bulgaria
-
Novartis Investigative Site
RECRUITINGLovech, 5500, Bulgaria
-
Novartis Investigative Site
RECRUITINGSofia, 1377, Bulgaria
-
Novartis Investigative Site
RECRUITINGVeliko Tarnovo, 5000, Bulgaria
-
Novartis Investigative Site
RECRUITINGVratsa, 3000, Bulgaria
-
Pillar Clinical Research LLC
RECRUITINGBentonville, Arkansas, 72712, United States
Contact
-
Pillar Clinical Research LLC
RECRUITINGChicago, Illinois, 60641, United States
Contact
-
Segal Institute for Clinical Research
RECRUITINGMiami, Florida, 33016, United States
Contact
-
Uptown Research Institute LLC
RECRUITINGChicago, Illinois, 60640, United States
Contact